mynth
← DATABASE
06/2016100%LBO

Atos Medical acquired by PAI Partners

SWEDEN Life Sciences / Medical Devices / Medical Consumables EV €500M–1.5bn

Context

PAI Partners has entered into a definitive agreement to acquire 100% of Atos Medical from EQT. This secondary LBO represents the 10th investment of the PAI Europe VI fund and marks the exit of EQT, which had overseen a period where the company doubled in size within five years. The current management team, led by CEO Claus Bjerre, remains in place to lead the next phase of the company's development under PAI's sponsorship. The strategic rationale for the acquisition is centered on the underpenetrated nature of the global laryngectomy market and the scalability of Atos Medical's direct-to-consumer model. PAI intends to leverage its healthcare sector capabilities to accelerate the company's transformational strategy, focusing on increased R&D investment and a broader global sales footprint. The deal is underpinned by the target's exceptional financial performance, including a 30% revenue growth in 2015 and industry-leading margins.

The acquisition of Atos Medical is part of the growth strategy of PAI Partners, which already has several external growth operations under its belt, notably Groupe B&B Hotels in 2015.

Atos Medical, which reported an EBITDA margin of [members only] in 2016, is valued in this transaction at an EV/EBITDA multiple of 10x–18x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1986, Atos Medical is the global market leader in laryngectomy care, specialized in supporting patients living with a neck stoma. The company’s core business model focuses on restoring speaking ability and improving pulmonary health for patients who have undergone surgical removal of the voice box or tracheostomy procedures. Its value proposition is built on a unique direct-to-consumer (DTC) model, which accounts for approximately 50% of its laryngectomy revenues, ensuring personalized care and long-term patient engagement. Atos Medical’s strategy emphasizes clinical innovation and geographical expansion, providing high-quality medical consumables such as heat and moisture exchangers (HMEs) and voice prostheses. By diversifying into the tracheostomy segment through selective acquisitions, the company has established itself as a comprehensive Ear, Nose, and Throat (ENT) specialist. With a direct presence in 30 countries and a distribution network reaching ~90 markets, Atos Medical combines technical medical expertise with a patient-centric service layer to maintain industry-leading margins and high organic growth.

Ent. Value

€500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

4x–10x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2016
€100–200M
€50–100M
[members only]
2015
€100–200M
€50–100M
[members only]

Other operations with Atos Medical

Other operations with Atos Medical
DateAcquirerTargetCountrySector
11/2021COLOPLASTATOS MEDICALSWEDENMedical Consumables

Other operations with PAI Partners

Other operations with PAI Partners
DateAcquirerTargetCountrySector
10/2017PAI PARTNERSREFRESCONETHERLANDSBeverages
05/2017PAI PARTNERSELITECH GROUPFRANCEDiagnostic Equipment
06/2016PAI PARTNERSETHYPHARMFRANCEPharma & Biotech
02/2016ADB SAFEGATE / PAI PARTNERSSAFEGATE INTERNATIONALSWEDENAerospace, Naval & Defense
12/2015PAI PARTNERSGROUPE B&B HOTELSFRANCEHotels & Accommodation
06/2014PAI PARTNERSDOMUSVIFRANCENursing Homes
06/2014PAI PARTNERSVPS HOLDINGSUNITED KINGDOMSecurity & Guarding
06/2014PAI PARTNERSLABEYRIE FINE FOODSFRANCEFood Products
04/2014PAI PARTNERS / THE CARLYLE GROUPINNOVISTA (EX CST)FRANCESensors & Optics
04/2014PAI PARTNERSEURO MEDIA GROUPFRANCEAudiovisual Production

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
09/2016ARCHIMEDPOLYPLUSFRANCER&D Biotech
09/2016ARDIAN / IXO PRIVATE EQUITYLAGARRIGUEFRANCEImplants & Prosthetics
06/2016PAI PARTNERSETHYPHARMFRANCEPharma & Biotech
06/2016BRIDGEPOINT / RAISE / FLEXSTONE PARTNERSACTEONFRANCEMedical Devices
05/2016IK PARTNERSMARLE GROUPFRANCEImplants & Prosthetics
03/2016PSP INVESTMENTSANTELLIQFRANCEAnimal Health
03/2016CVCDOC GENERICIITALYGenerics / Labs
02/2016TE CONNECTIVITYCREGANNA MEDICALIRELANDMedical Devices
02/2016ASTORG / GOLDMAN SACHSHRA PHARMAFRANCEGenerics / Labs
07/2015PERRIGO COMPANYNATURWOHL PHARMA (YOKEBE)GERMANYGenerics / Labs

REFERENCES

Valuation range: EV €500M–1.5bn

Revenue range: €100–200M

EBITDA range: €50–100M

EV/Revenue range: 4x - 10x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Atos Medical by PAI Partners are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: atos medical

FAQ

What transaction does this page cover?

This page covers PAI Partners’s acquisition of 100% of Atos Medical, a Swedish company specialised in Medical Devices, in 2016, structured as a leveraged buyout (LBO). Ownership has since evolved, leading to a subsequent transaction with Coloplast in November 2021 (see the dedicated deal page for details).

How was the acquisition of Atos Medical by PAI Partners valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €500M–1.5bn band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 4x - 10x range. Exact figures are available to members.

What were Atos Medical’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Atos Medical generated annual revenue estimated in the €100–200M range and EBITDA in the €50–100M bracket (FY 2016). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction intelligence is supported by independent reporting from specialized financial publications, alongside a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.